A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2020-05-05
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants
with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a
16-week treatment period, and an 8-week follow-up period.